Clinical Studies

Building Clinical Evidence for Predictive Alzheimer’s Diagnostics

Toward A Future Where Alzheimer’s Can Be Predicted Earlier

Today, most Alzheimer’s biomarker tests focus on detecting amyloid pathology. AgenT is building something different: blood-based predictive tests designed to identify whether an individual is likely to progress to Alzheimer’s dementia symptoms. Through APOLLO I and APOLLO II, AgenT is training and validating predictive algorithms on longitudinal plasma samples from 20+ cohorts across the US, Europe, and Australia. By combining proprietary multiomics biomarkers, machine learning, and clinical follow-up, these algorithms are designed to predict disease progression before irreversible decline.

By building robust clinical evidence, the APOLLO program supports AgenT’s path toward future regulatory submissions, clinical adoption, patient stratification, and precision medicine in Alzheimer’s disease.

Highest Standards

Our goal is to make our blood tests accessible to everyone who could benefit from them. We are developing the clinical and health economic evidence required for FDA and other regulatory approvals, inclusion in Alzheimer’s care guidelines, and future reimbursement.

Current Clinical Studies

APOLLO I

APOLLO I was designed to validate our blood-based multiomics approach to Alzheimer’s disease prediction. The study evaluated whether proprietary plasma biomarkers and machine learning algorithms could predict progression to Alzheimer’s dementia using longitudinal human samples.

Current Status: Completed

APOLLO II

APOLLO II is our pivotal clinical validation study designed to generate the clinical evidence required to support FDA approval of our blood-based predictive tests for Alzheimer’s disease. The study is validating algorithms designed to predict progression to Alzheimer’s dementia in cognitively impaired and unimpaired individuals.

Current Status: Ongoing

Partner With Us To Advance Neurodegenerative Disease Research

We collaborate with clinical centers, pharma and biotech companies, laboratory networks, and research partners to advance blood-based tools for earlier detection, patient stratification, and treatment development in neurodegenerative diseases.